Pyxis Oncology stock faces wide analyst targets despite losses
Published on 10/30/2026 at 03:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst views and biotech risks
- Ten brokerages cover Pyxis Oncology, with eight buy ratings, one hold and one sell.
- The company remains a clinical-stage biotechnology business without a profitable operating record.
- Analyst targets range widely, underscoring the uncertainty around clinical development and valuation.
MarketBeat reported on October 29, 2026 that analysts maintain a moderately positive view of Pyxis Oncology, while the company remains an unprofitable clinical-stage biotechnology business. The report said ten brokerages cover the stock and set an average 12-month price target of USD 8.75.
Broad range of analyst views
The consensus comprises eight buy ratings, one hold and one sell. Individual targets remain widely dispersed: Wells Fargo raised its target from USD 12 to USD 19 and assigned an overweight rating, while other firms cited in the report placed targets between USD 7 and USD 8. Leerink Partners lowered its target from USD 9 to USD 7, and Weiss Ratings reiterated a sell rating.
The spread is relevant for investors because valuation in a clinical-stage biotechnology company depends heavily on the progress and eventual commercial potential of its development programs. The analyst figures are estimates rather than company guidance and do not establish a likely trading price.
Losses keep risk elevated
MarketBeat also reported that Pyxis Oncology recently posted an adjusted loss of USD 0.40 per share, compared with a consensus estimate of a USD 0.35 loss. The company develops antibody-based cancer therapies, including antibody-drug conjugates and immunotherapies aimed at difficult-to-treat cancers.
For investors, the combination of a broad target range, ongoing losses and dependence on clinical progress points to a high-risk profile. Analyst optimism therefore needs to be weighed against trial, financing and execution risks.
Pyxis Oncology at a glance
- Company: Pyxis Oncology, Inc.
- ISIN: US7473241013
- Ticker: PYXS
- Analyst consensus: Moderate Buy from ten brokerages
- Average 12-month target: USD 8.75
The broader US market provides the relevant trading context for this US-listed biotechnology company. Current market developments around the S&P 500 can influence risk appetite for speculative growth shares.
